BiotechTube

BEZ235 + MEK162

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unspecified Adult Solid Tumor, Protocol Specific

Conditions

Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor

Trial Timeline

Jul 8, 2011 → Mar 22, 2013

NCT ID
NCT01337765

About BEZ235 + MEK162

BEZ235 + MEK162 is a phase 1 stage product being developed by Pfizer for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT01337765. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01337765Phase 1Completed

Competing Products

20 competing products in Unspecified Adult Solid Tumor, Protocol Specific

See all competitors
ProductCompanyStageHype Score
DJ-927 + capecitabineDaiichi SankyoPhase 1
33
E7389 + E7389 + E7389EisaiPhase 1
33
bevacizumab + enzastaurin hydrochlorideEli LillyPhase 1
33
SHR-1916Jiangsu Hengrui MedicinePhase 1
33
PembrolizumabMerckPhase 2
52
PI3K inhibitor BKM120 + docetaxelNovartisPhase 1
33
bevacizumab + cyclophosphamide + imatinibNovartisPhase 1
33
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)NovartisPhase 1
33
warfarinNovartisPhase 1
33
RLY-1971RochePhase 1
33
Domvanalimab + ZimberelimabGilead SciencesPhase 1
32
Utomilumab + ISA101bPfizerPhase 2
51
IrinotecanPfizerPhase 1
32
Ixabepilone + SunitinibPfizerPhase 1
32
ixabepilone + lapatinib ditosylateBristol Myers SquibbPhase 1
32
carboplatin + irinotecan hydrochlorideBristol Myers SquibbPhase 1
32
intoplicineSanofiPhase 1
32
apomineSanofiPhase 1
32
apomineSanofiPhase 1
32
SorafenibBayerPhase 2
49

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84